Difference between revisions of "MAPT-AS1"
| Line 19: | Line 19: | ||
| | 5’-UUACUUAUCCAUGAAGUGGgt-3’<ref name="ref2" /> | | | 5’-UUACUUAUCCAUGAAGUGGgt-3’<ref name="ref2" /> | ||
|} | |} | ||
| + | ===Function=== | ||
| + | MAPT-AS1 has an inhibitory effect on the expression of a major neurodegenerative gene, MAPT. MAPT-AS1 may serve as a sensitive biomarker of disease state in Parkinson’s disease, as well as a potential therapeutic target for inhibiting the expression of MAPT. <ref name="ref2" /> | ||
| + | ==Labs working on this lncRNA== | ||
| + | * Genomics Institute, University of California Santa Cruz, Santa Cruz, CA 95064, USA.<ref name="ref1" /> | ||
| + | * Neuroscience Research Australia, Randwick, NSW, Australia.<ref name="ref2" /> | ||
| + | * School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.<ref name="ref2" /> | ||
| + | ==References== | ||
| + | <references> | ||
| + | <ref name="ref1"> Speir, M.L., et al., The UCSC Genome Browser database: 2016 update. Nucleic Acids Res, 2016. 44(D1): p. D717-25. | ||
| + | </ref>(1) | ||
| + | <ref name="ref2">Coupland, K.G., et al., Role of the Long Non-Coding RNA MAPT-AS1 in Regulation of Microtubule Associated Protein Tau (MAPT) Expression in Parkinson's Disease. PLoS One, 2016. 11(6): p. e0157924. | ||
| + | </references> | ||
Revision as of 14:53, 22 October 2017
Contents
Annotated Information
Approved Symbol
MAPT-AS1 (MAPT antisense RNA 1)
Chromosome
17q21.31
Effect of MAPT-AS1 over- and knock-down expression on MAPT expression in HEK293 and SK-N-MC cells. [1].
RefSeq(supplied by NCBI)
NR_024559
Characteristics
MAPT-AS1 is an 840 bp lncRNA transcribed from the anti-sense strand of the MAPT promoter region.[1]
Expression
The siRNA s237111 can Knock-down the expression of MAPT-AS1.The sequence of the s237111 siRNA is described in the table below.[2]
| sense | antisense |
|---|---|
| 5’-CCACUUCAUGGAUAAGUAAtt-3’ | 5’-UUACUUAUCCAUGAAGUGGgt-3’[2] |
Function
MAPT-AS1 has an inhibitory effect on the expression of a major neurodegenerative gene, MAPT. MAPT-AS1 may serve as a sensitive biomarker of disease state in Parkinson’s disease, as well as a potential therapeutic target for inhibiting the expression of MAPT. [2]
Labs working on this lncRNA
- Genomics Institute, University of California Santa Cruz, Santa Cruz, CA 95064, USA.[1]
- Neuroscience Research Australia, Randwick, NSW, Australia.[2]
- School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.[2]
